Adamas Pharmaceuticals, Inc. (ADMS)
(Delayed Data from NSDQ)
$6.39 USD
+0.11 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.38 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.39 USD
+0.11 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.38 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in the Card's for Sealed Air (SEE) in Q2 Earnings?
by Zacks Equity Research
Sealed Air's (SEE) second-quarter 2018 results are likely to reflect benefits from rising demand for packaged proteins and convenience meals amid cost concerns.
Acorda Files Parkinson's Drug Marketing Application in EU
by Zacks Equity Research
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
Pharma Stocks Weighed Down by Competition, Generic Pressure
by Zacks Equity Research
Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.
New Strong Sell Stocks for February 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
FDA Accepts Acorda's NDA for Parkinson's Disease Candidate
by Zacks Equity Research
FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.
Parkinson's Disease Space Again Under Spotlight This Week
by Zacks Equity Research
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up
by Zacks Equity Research
Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.
Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops
by Zacks Equity Research
Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.
Acorda Reports Death in Parkinson's Trials, Stock Down 40%
by Zacks Equity Research
Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.
Adamas Pharmaceuticals (ADMS) Stock Soars 41% After FDA Approval
by Megan Sanks
Adamas Pharmaceuticals, Inc. (ADMS) skyrocketed 41% in midday trading on Friday after the Food and Drug Administration approved its Parkinson's drug, Gocovri.
Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
by Zacks Equity Research
Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options
by Zacks Equity Research
High level of implied volatility makes Adamas Pharmaceuticals (ADMS) Stock lucrative to the option traders.
Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)
by Zacks Equity Research
One stock that you may want to consider dropping is Adamas Pharmaceuticals, Inc. (ADMS), which has witnessed a significant price decline in the past four weeks
Adamas Provides Positive Long-term Data on Parkinson's Drug
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.
Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) saw its shares rise above 5% in the last trading session.
Mylan (MYL) Announces Multiple Generic Launches in the U.S.
by Zacks Equity Research
Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.
Mylan/Biocon's Herceptin Biosimilar Phase III Data Published
by Zacks Equity Research
Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.
Mylan (MYL) Launches Authorized Generic EpiPen at $300
by Zacks Equity Research
Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.
Is Cooper Companies (COO) Poised for Earnings Beat in Q4?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report fourth-quarter fiscal 2016 results after the market closes on Dec 8.